Investigator-initiated and open-labeled clinical trial for evaluation of maximum tolerented dose, safety and efficiency of MSC11FCD therapy to recurrent glioblastoma patients
Investigator-initiated and Open-labeled Clinical Trial for Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
This is a phase I trial evaluating the maximum tolerated dose, safety and efficiency of Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD), injected into the resection cavity of patients with recurrent glioblastoma.
100 项与 MSC11FCD 相关的专利(医药)